Dr Andrea Luk is an endocrinologist and is currently Professor of the Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong. She is also the Director of the CUHK Clinical Research Management Office, Medical Director (non-oncology) of the CUHK Phase 1 Clinical Trial Centre, and serves as an Honorary Consultant at the Prince of Wales Hospital. Dr Luk obtained her Bachelor of Medicine and Surgery at the University of Auckland, New Zealand, and completed her specialist training in Endocrinology, Diabetes and Metabolism in Hong Kong in 2007. Dr Luk’s research interests include diabetes epidemiology, young-onset diabetes, and translational research related to diabetes care paths. Dr Luk leads the analysis of a large database of close to 1 million people with diabetes in Hong Kong. She has received multiple competitive research grants and has been the principal or co-investigator of over 120 clinical trials on treatment of diabetes and obesity. Dr Luk has published over 220 articles in peer reviewed journals and contributed to developing the 10th and 11th edition of the International Diabetes Federation Atlas. She has received several awards including the Xiaoren Pan Distinguished Research Award for Epidemiology of Diabetes in Asia in 2022 and the Harry Keen Memorial Award of the International Diabetes Epidemiology Group in 2019.

Belinda Lin serves as the Life Sciences Ecosystem Development Lead at the Hong Kong-Shenzhen Innovation and Technology Park (HSITP), where she fosters collaboration among scientists, entrepreneurs, investors, industry leaders, and policymakers to build Hong Kong’s largest emerging innovation hub. With a mission to accelerate R&D to commercialisation by bridging cutting-edge research with market-ready solutions, Belinda draws on over a decade of experience in the pharmaceutical industry - focused on medical affairs and clinical development across Asia-Pacific and global markets. She holds a PhD in biology from the University of Goettingen, supported by the Croucher Foundation, and conducted postdoctoral research in drug discovery at Washington University School of Medicine. Deeply committed to the scientific and healthcare communities, she values every opportunity to learn from and contribute to those driving meaningful impact.

Dr. Yuwen Chen is a distinguished toxicologist with over 15 years of expertise in preclinical drug development, specializing in toxicology and global regulatory compliance. As a Diplomate of the American Board of Toxicology, she has led over 200 GLP studies, contributing to over 40 successful IND approvals. In China, as Executive Director and Vice President at Suzhou Frontage (2022–present), she achieved China NMPA GLP certification for a toxicology facility within one year. In the UK, as Senior Study Director at Labcorp (2019–2022), she directed biopharmaceutical toxicology studies. At Covance Shanghai (2016–2019), she developed safety pharmacology assays, earning “Team of the Year” in 2018. Holding a PhD in Veterinary Clinical Science from the University of Illinois at Urbana-Champaign and a DVM from National Chung Hsing University, Dr. Chen’s leadership and scientific rigor drive innovation. Her commitment to advancing drug development makes her an ideal partner for pharmaceutical collaborations.

He graduated from the University of New South Wales in Australia with a Doctor of Philosophy (PhD) degree in Microbiology and Immunology. He has long been engaged in research in the fields of bioinformatics and genomics, having published more than 20 academic papers in international core scientific journals such as PNAS and ISME, and holds 4 national invention patents.